| Zacks Company Profile for Zentalis Pharmaceuticals, Inc. (ZNTL : NSDQ) |
|
|
| |
| • Company Description |
| Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company's lead programs consist of ZN-c5, an oral selective estrogen receptor degrader for estrogen-receptor-positive, HER2-negative breast cancer which is in clinical stage. It operates principally in New York and San Diego. Zentalis Pharmaceuticals, Inc. is based in NEW YORK.
Number of Employees: 166 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $2.57 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 650,867 shares |
| Shares Outstanding: 70.93 (millions) |
| Market Capitalization: $182.29 (millions) |
| Beta: 1.65 |
| 52 Week High: $3.95 |
| 52 Week Low: $1.01 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
2.39% |
6.97% |
| 12 Week |
6.20% |
11.78% |
| Year To Date |
90.37% |
98.19% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
10275 SCIENCE CENTER DRIVE SUITE 200
-
SAN DIEGO,CA 92121
USA |
ph: 858-263-4333
fax: - |
ehickin@zentalis.com |
https://zentalis.com |
|
|
| |
| • General Corporate Information |
Officers
Julie Eastland - President; Chief Executive Officer and Director
Scott Myers - Chairperson
Vincent A. Vultaggio - Senior Vice President; Finance and Principal Accou
David Johnson - Director
Enoch Kariuki - Director
|
|
Peer Information
Zentalis Pharmaceuticals, Inc. (CORR.)
Zentalis Pharmaceuticals, Inc. (RSPI)
Zentalis Pharmaceuticals, Inc. (CGXP)
Zentalis Pharmaceuticals, Inc. (BGEN)
Zentalis Pharmaceuticals, Inc. (GTBP)
Zentalis Pharmaceuticals, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 98943L107
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/25
Next Expected EPS Date: 05/13/26
|
|
Share - Related Items
Shares Outstanding: 70.93
Most Recent Split Date: (:1)
Beta: 1.65
Market Capitalization: $182.29 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.45 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-1.89 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 6.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 05/13/26 |
|
|
|
| |
